{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:02:25Z","timestamp":1790780545469,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01018-7","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:23Z","timestamp":1790779943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives of Adult Patients and Caregivers on the Management and Challenges Associated with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Multinational Qualitative Survey"],"prefix":"10.1007","author":[{"given":"Ayo","family":"Adeyemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Burckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Buttarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Ferner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Crites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/gim.2017.215","volume":"20","author":"RA Kallionpaa","year":"2018","unstructured":"Kallionpaa RA, Uusitalo E, Leppavirta J, Poyhonen M, Peltonen S, Peltonen J. Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med. 2018;20:1082\u20136.","journal-title":"Genet Med"},{"key":"1018_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"TJ Lee","year":"2023","unstructured":"Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18:292.","journal-title":"Orphanet J Rare Dis"},{"key":"1018_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02493-5","volume":"17","author":"C Barnett","year":"2022","unstructured":"Barnett C, Candido E, Chen B, Pequeno P, Parkin PC, Tu K. Development of algorithms to identify individuals with neurofibromatosis type 1 within administrative data and electronic medical records in Ontario, Canada. Orphanet J Rare Dis. 2022;17:321.","journal-title":"Orphanet J Rare Dis"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/nov200","volume":"18","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18:624\u201338.","journal-title":"Neuro Oncol"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834\u201343.","journal-title":"Lancet Neurol"},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81\u20138.","journal-title":"J Med Genet"},{"key":"1018_CR7","first-page":"1993","volume-title":"GeneReviews\u00ae [Internet]","author":"JM Friedman","year":"2022","unstructured":"Friedman JM, et al. Neurofibromatosis 1. In: Adam MP, Feldman J, Mirzaa GM, editors., et al., GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 2022. p. 1993\u20132025."},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/nop\/npac014","volume":"9","author":"TA Gregory","year":"2022","unstructured":"Gregory TA, Molina PSB, Phillips GD, Henson JW. Impact of neurofibromatosis type 1 in an adult community population. Neuro-oncol Pract. 2022;9:229\u201335.","journal-title":"Neuro-oncol Pract"},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ajmg.a.61069","volume":"179","author":"AM Kongkriangkai","year":"2019","unstructured":"Kongkriangkai AM, King C, Martin LJ, et al. Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis type 1. Am J Med Genet A. 2019;179:602\u20137.","journal-title":"Am J Med Genet A"},{"key":"1018_CR10","unstructured":"Alexion. Selumetinib (Koselugo) Full Prescribing Information. https:\/\/alexion.com\/Documents\/koselugo_uspi.pdf. Accessed 22 Dec, 2025."},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","volume":"15","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Servy A, Valeyrie-Allanore L, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15:37.","journal-title":"Orphanet J Rare Dis"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1002\/ajmg.a.35550","volume":"158a","author":"SA Madanikia","year":"2012","unstructured":"Madanikia SA, Bergner A, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. Am J Med Genet A. 2012;158a:3056\u201360.","journal-title":"Am J Med Genet A"},{"key":"1018_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101818","volume":"56","author":"C Carton","year":"2023","unstructured":"Carton C, Evans DG, Blanco I, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.","journal-title":"EClinicalMedicine"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34:1978\u201386.","journal-title":"J Clin Oncol"},{"key":"1018_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071930","volume":"15","author":"A Pellerino","year":"2023","unstructured":"Pellerino A, Verdijk RM, Nichelli L, Andratschke NH, Idbaih A, Goldbrunner R. Diagnosis and treatment of peripheral and cranial nerve tumors with expert recommendations: an EUropean Network for RAre CANcers (EURACAN) initiative. Cancers (Basel). 2023;15:1930.","journal-title":"Cancers (Basel)"},{"key":"1018_CR16","first-page":"55","volume":"12","author":"C Copley-Merriman","year":"2021","unstructured":"Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review. Adolesc Health Med Ther. 2021;12:55\u201366.","journal-title":"Adolesc Health Med Ther"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4103\/ijnmr.IJNMR_178_20","volume":"26","author":"S Foji","year":"2021","unstructured":"Foji S, Mohammadi E, Sanagoo A, Jouybari L. The patients\u2019 experiences of burden of neurofibromatosis: a qualitative study. Iran J Nurs Midwifery Res. 2021;26:342\u20138.","journal-title":"Iran J Nurs Midwifery Res"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12883-019-1338-y","volume":"19","author":"A Sanagoo","year":"2019","unstructured":"Sanagoo A, Jouybari L, Koohi F, Sayehmiri F. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol. 2019;19:123.","journal-title":"BMC Neurol"},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167A","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A:2103\u201313.","journal-title":"Am J Med Genet A"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20:1643\u201351.","journal-title":"Neuro Oncol"},{"key":"1018_CR21","first-page":"330","volume":"10","author":"ND Cavallo","year":"2023","unstructured":"Cavallo ND, Maggi G, Ferraiuolo F, et al. Neuropsychiatric manifestations, reduced self-esteem and poor quality of life in children and adolescents with neurofibromatosis type 1 (NF1): the impact of symptom visibility and bullying behavior. Children (Basel). 2023;10:330.","journal-title":"Children (Basel)"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13023-021-01866-6","volume":"16","author":"FD Buono","year":"2021","unstructured":"Buono FD, Sprong ME, Paul E, Martin S, Larkin K, Garakani A. The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with neurofibromatosis Type 1. Orphanet J Rare Dis. 2021;16:234.","journal-title":"Orphanet J Rare Dis"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40120-022-00365-5","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang X, Yoo HK, Amin S, et al. Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States: a cross-sectional study. Neurol Ther. 2022;11:1221\u201333.","journal-title":"Neurol Ther"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"205031211982968","DOI":"10.1177\/2050312119829680","volume":"7","author":"A Heaney","year":"2019","unstructured":"Heaney A, Wilburn J, Langmead S, et al. A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1. SAGE Open Med. 2019;7:2050312119829680.","journal-title":"SAGE Open Med"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/ajmg.a.38680","volume":"176","author":"AB Rietman","year":"2018","unstructured":"Rietman AB, van Helden H, Both PH, et al. Worries and needs of adults and parents of adults with neurofibromatosis type 1. Am J Med Genet A. 2018;176:1150\u201360.","journal-title":"Am J Med Genet A"},{"key":"1018_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12883-023-03429-7","volume":"23","author":"HK Yoo","year":"2023","unstructured":"Yoo HK, Porteous A, Ng A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023;23:419.","journal-title":"BMC Neurol"},{"key":"1018_CR27","unstructured":"European Medicines Agency. Koselugo. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/koselugo. Accessed 22 Dec, 2025."},{"key":"1018_CR28","unstructured":"AstraZeneca. Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas.html. Accessed 22 Dec, 2025."},{"key":"1018_CR29","unstructured":"AstraZeneca. Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html. Accessed 22 Dec, 2025."},{"key":"1018_CR30","unstructured":"USA Food and Drug Administration. FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. Accessed 22 Dec, 2025."},{"key":"1018_CR31","unstructured":"U.S. Food and Drug Administration. FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic#:~:text=On%20February%2011%2C%202025%2C%20the,not%20amenable%20to%20complete%20resection. Accessed 24 Aug, 2026."},{"key":"1018_CR32","unstructured":"EMA. Ezmekly (mirdametinib). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ezmekly. Accessed 13 Aug, 2025."},{"key":"1018_CR33","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405:2217\u201330.","journal-title":"Lancet"},{"key":"1018_CR34","unstructured":"USA Food and Drug Administration. FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. Accessed 22 Dec, 2025."},{"key":"1018_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","volume":"11","author":"C Ejerskov","year":"2023","unstructured":"Ejerskov C, Farholt S, Nielsen FSK, et al. Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in Denmark: a nationwide study. Oncol Ther. 2023;11:97\u2013110.","journal-title":"Oncol Ther"},{"key":"1018_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10996-y","volume":"23","author":"AE Armstrong","year":"2023","unstructured":"Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer. 2023;23:553.","journal-title":"BMC Cancer"},{"key":"1018_CR37","unstructured":"European Pharmaceutical Market Research Association. Guidelines\/Codes of Conduct. https:\/\/www.bhbia.org.uk\/guidelines-and-legislation. Accessed 18 Mar, 2026."},{"key":"1018_CR38","unstructured":"British Healthcare Business Intelligence Association. Guidelines & Legislation. https:\/\/www.bhbia.org.uk\/guidelines-and-legislation. Accessed 18 Mar, 2026."},{"key":"1018_CR39","unstructured":"COPE. Guidance and tools. https:\/\/publicationethics.org\/guidance-and-tools. Accessed 18 Mar, 2026."},{"key":"1018_CR40","unstructured":"ESOMAR. Professional Research Guidelines. https:\/\/esomar.org\/guidelines. Accessed 18 Mar, 2026."},{"key":"1018_CR41","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:671\u201382.","journal-title":"Genet Med"},{"key":"1018_CR42","doi-asserted-by":"publisher","first-page":"T187","DOI":"10.1016\/j.ad.2022.10.043","volume":"114","author":"FJ Garcia-Martinez","year":"2023","unstructured":"Garcia-Martinez FJ, Hernandez-Martin A. [Translated article] Neurofibromatosis type 1: diagnostic timelines in children. Actas Dermosifiliogr. 2023;114:T187\u201393.","journal-title":"Actas Dermosifiliogr"},{"key":"1018_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1023\/A:1022020000598","volume":"7","author":"M Ponder","year":"1998","unstructured":"Ponder M, Murton F, Hallowell N, Statham H, Green J, Richards M. Genetic counseling, reproductive behavior and future reproductive intentions of people with neurofibromatosis type 1 (NF1). J Genet Couns. 1998;7:331\u201344.","journal-title":"J Genet Couns"},{"key":"1018_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178639","volume":"12","author":"M Seidlin","year":"2017","unstructured":"Seidlin M, Holzman R, Knight P, et al. Characterization and utilization of an international neurofibromatosis web-based, patient-entered registry: an observational study. PLoS ONE. 2017;12:e0178639.","journal-title":"PLoS ONE"},{"key":"1018_CR45","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/cancers16061119","volume":"16","author":"S Rana","year":"2024","unstructured":"Rana S, Low CE, Karthikeyan M, Koh MJA, Ngeow J, Chiang J. A systematic review of diagnostic modalities and strategies for the assessment of complications in adult patients with neurofibromatosis type 1. Cancers. 2024;16:1119.","journal-title":"Cancers"},{"key":"1018_CR46","unstructured":"Bischoff K, Erickson G, Franson A, et al. Challenges in the transition from pediatric to adult healthcare faced by patients with neurofibromatosis type 1. https:\/\/www.nfnetwork.org\/data\/uploads\/news-pics\/2025\/2024_Transition_of_Care_Roundtable_White_Paper_Jan2025_Final.pdf. Accessed 25 Apr, 2025."},{"key":"1018_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/PHMT.S362679","volume":"14","author":"HB Radtke","year":"2023","unstructured":"Radtke HB, Berger A, Skelton T, Goetsch WA. Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care. Pediatric Health Med Ther. 2023;14:19\u201332.","journal-title":"Pediatric Health Med Ther"},{"key":"1018_CR48","doi-asserted-by":"publisher","first-page":"1398803","DOI":"10.3389\/fpubh.2024.1398803","volume":"12","author":"W Liang","year":"2024","unstructured":"Liang W, Cao S, Suo Y, et al. Long-term distress throughout one\u2019s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China. Front Public Health. 2024;12:1398803.","journal-title":"Front Public Health"},{"key":"1018_CR49","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jpsychires.2022.07.035","volume":"154","author":"A Del Castillo","year":"2022","unstructured":"Del Castillo A, Dekarchuk M, Inker T, Hussey M, Walsh KS. Understanding the neurofibromatosis type 1 (NF1) experience and the priorities of individuals with NF1 and their caregivers for cognitive and social-emotional research. J Psychiatr Res. 2022;154:268\u201377.","journal-title":"J Psychiatr Res"},{"key":"1018_CR50","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"CE Prada","year":"2012","unstructured":"Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012;160:461\u20137.","journal-title":"J Pediatr"},{"key":"1018_CR51","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","volume":"131","author":"MN Needle","year":"1997","unstructured":"Needle MN, Cnaan A, Dattilo J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children\u2019s Hospital of Philadelphia experience, 1974\u20131994. J Pediatr. 1997;131:678\u201382.","journal-title":"J Pediatr"},{"key":"1018_CR52","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1684\/ejd.2020.3869","volume":"30","author":"M Koga","year":"2020","unstructured":"Koga M, Yoshida Y, Ehara Y, Imafuku S. Medical costs of surgical intervention for hospitalized patients with neurofibromatosis 1 in Japan. Eur J Dermatol. 2020;30:618\u201320.","journal-title":"Eur J Dermatol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01018-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:27Z","timestamp":1790779947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01018-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":52,"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01018-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ayo Adeyemi and Michelle Erdmann are employees of, and own stocks in, Alexion, AstraZeneca Rare Disease. At the time of the study, Susanna Burckhardt was an employee of Alexion, AstraZeneca Rare Disease and still owns stocks in AstraZeneca. Abby Crites is an employee of IQVIA and has conducted market research studies with patients, healthcare professionals, and payers on behalf of Alexion, AstraZeneca Rare Disease. Rosalie Ferner is a medical advisor for Alexion. Riccardo Buttarelli, Brendon Pommier, Geting Su, and Hui Zhang declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Review by an Institutional Review Board (IRB) was not required, as this study aligns with established international ethical standards for non-interventional qualitative research and, therefore, meets the criteria for exemption from formal institutional ethics board review. Several globally recognized frameworks, including the European Pharmaceutical Market Research Association [EPHMRA] guidelines and code of conduct [\n                      \n                      ], the British Healthcare Business Intelligence Association [BHBIA] guidelines and legislation [\n                      \n                      ], COPE guidance and tools [\n                      \n                      ], and ESOMAR Global Voice of Research, Data and Insights professional research guidelines [\n                      \n                      ], consistently affirm that anonymized, opinion-based, qualitative research with no clinical intervention does not constitute human subjects research requiring formal IRB review. The study is therefore appropriately classified as exempt under widely recognized international ethical standards governing healthcare market and outcomes research. Honoraria were provided at fair market value for participation in 45-min interviews. Informed consent was obtained from every participant prior to participation in the study before the interviews started. Participants were explicitly informed about how their data would be used, including their right to withdraw from the study at any time. While participants were not specifically told that the study results would be published, they were clearly informed that their responses would be reported only in aggregate form and that their identities would remain anonymous throughout all stages of analysis and dissemination.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}